Filing Flows

Filing Flows › Pacira BioSciences (PCRX) › Who owns the stock

Who owns Pacira BioSciences (PCRX) stock

243 funds reported Pacira BioSciences (PCRX) shares in their latest 13F filings, worth $1.2B in all. The largest holder is BlackRock ($170M). Last quarter 104 funds added to their stakes and 101 cut them.

Largest holders of PCRX (13F)Largest holders of PCRX (13F)BlackRock$170MVanguard Group$125MDoma Perpetual Capital Management…$70.5MVanguard Portfolio Management LLC$61.0MDimensional Fund Advisors LP$53.4MState Street$52.3MD. E. Shaw$49.5MRenaissance Technologies LLC$44.0MVanguard Capital Management LLC$42.9MGoldman Sachs Group$38.7M

Largest holders (13F)

FundSharesValueChangeQuarter
BlackRock6,705,809$170Mdecrease2026-06-30
Vanguard Group4,812,955$125Mdecrease2025-12-31
Doma Perpetual Capital Management LLC2,777,794$70.5Munchanged2026-06-30
Vanguard Portfolio Management LLC2,406,238$61.0Mdecrease2026-06-30
Dimensional Fund Advisors LP2,103,245$53.4Mincrease2026-06-30
State Street2,059,977$52.3Mincrease2026-06-30
D. E. Shaw1,950,332$49.5Mdecrease2026-06-30
Renaissance Technologies LLC1,733,801$44.0Mdecrease2026-06-30
Vanguard Capital Management LLC1,691,571$42.9Mdecrease2026-06-30
Goldman Sachs Group1,527,129$38.7Mdecrease2026-06-30
Geode Capital Management, LLC1,158,693$29.4Mincrease2026-06-30
Morgan Stanley1,144,654$29.0Mdecrease2026-06-30
American Century Companies1,018,093$25.8Mincrease2026-06-30
UBS Group AG920,217$23.3Mincrease2026-06-30
Impax Asset Management Group750,027$19.0Munchanged2026-06-30

Pacira BioSciences' latest quarter

Pacira BioSciences, Q3 2026: revenue $177M (-2% year over year), operating margin 12.6%, net earnings $28.5M, operating cash flow $50.1M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most PCRX stock?

By the latest 13F filings: BlackRock ($170M); Vanguard Group ($125M); Doma Perpetual Capital Management LLC ($70.5M); Vanguard Portfolio Management LLC ($61.0M); Dimensional Fund Advisors LP ($53.4M).

What is the short interest in PCRX?

4,260,076 shares were sold short at the 2026-10-15 settlement, -47.25% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.